Novavax INC Schedule 13D activist filings

Shah Capital Management has submitted an amendment to its Schedule 13D filing, criticizing Novavax's current leadership and outlining perceived failures in marketing, partnerships, capital management, and executive compensation.

Shah Capital Management, a significant shareholder, has announced its intention to vote against Novavax's board nominees and executive compensation, citing value destruction and operational failures.

Shah Capital, an 8.3% shareholder, publicly criticized Novavax's management for operational failures, high costs, and poor vaccine rollout, urging the board to seek a sale to a larger pharma company.

Activist investor Shah Capital, holding 7.3% of Novavax, demands an immediate strategic review and potential sale of the company, citing persistent underperformance and operational failures.